The company intends to use the funds to build its headquarters, laboratory and manufacturing space in Danbury.
Founded in 2011 and led by Solomon Steiner, president and CEO, Perosphere is focused on developing rescue medications. Its lead drug candidate, a reversal agent for new oral anticoagulants, is currently in Phase II clinical trials. The company also has programs directed at ultra-rapid-acting insulin lispro; repurposing felbamate as a neuroprotective for traumatic brain injury; and rapid desensitization to peanuts in allergic individuals.
Perosphere’s headquarters will house more than 30 employees in a 16,000 square feet stand-alone building, including 12,000 square feet of laboratory and manufacturing space.